Tag Archive for: Cancer

Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin®

/in

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 Oslo, Norway, 18 June 2026: Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of […]

Read more

Poolbeg Pharma plc – Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS

/in

Major milestone will provide IP protection in key European markets, strengthening global patent portfolio 16 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced […]

Read more

Poolbeg Pharma plc – Two posters with POLB 001 preclinical data presented at the European Hematology Association Congress

/in

Posters highlight POLB 001’s potential in CRS prevention and ability to enhance AML treatment in elderly patients, potentially expanding into a new indication  ·    First poster shows that POLB 001 decreased key CRS-associated cytokines and did not impair bispecific antibody-induced tumour cell death in a series of preclinical investigations ·    Second poster demonstrates the potential for POLB […]

Read more

Poolbeg Pharma announces successful site activation for POLB 001 TOPICAL clinical trial

/in

Major operational milestone achieved with interim data on track for summer 2026 11 June 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the first site activation for the first-in-patient POLB 001 TOPICAL* clinical trial has occurred. This follows the successful completion of […]

Read more

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

/in

Oversubscribed Series B financing co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer Financing supports Ona’s transition […]

Read more
© Optimum Strategic Communications.